SynthesisClinical rheumatology2021
Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.
Synthesis in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 8 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.The Journal of thoracic and cardiovascular surgery · 2023Guideline
- Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.Frontiers in immunology · 2023Pooled it
- Guideline
- 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2022Guideline
- Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2022Pooled it
- A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.Clinical rheumatology · 2022Pooled it
- Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis.Rheumatology international · 2021Pooled it
- Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.Rheumatology (Oxford, England) · 2025Trial
- The Effectiveness of Janus Kinase Inhibitors for the Management of Relapsing Takayasu Arteritis: A Spanish Real-World Study and Comprehensive Review of the Literature.Life (Basel, Switzerland) · 2026Article
- Syncope as the Initial Presentation of Takayasu Arteritis in a 57-Year-Old Female: A Case Report and Literature Review.Clinical case reports · 2026Article
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience.RMD open · 2026Article
- Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification.Circulation · 2026Review
- Monocyte/Macrophage Subsets in the Peripheral Blood, Their Related Cytokines, and Circulating Markers of Fibrosis in Active Takayasu Arteritis and Longitudinal Changes Following Immunosuppressive Therapy.Journal of inflammation research · 2026Article
- Interventions Related to Takayasu Arteritis, their Clinical and Angiographic Associations, and Prognostic Relevance - A Cohort Study.Mediterranean journal of rheumatology · 2025Article
- [News on the treatment of large vessel vasculitis].Zeitschrift fur Rheumatologie · 2024Review
- Takayasu's Arteritis: A Special Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study.RMD open · 2024Article
- Chinese guideline for the diagnosis and treatment of Takayasu's arteritis (2023).Rheumatology and immunology research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science, Pubmed Central, clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in TAK identified four randomized controlled trials (RCTs, with another longer-term follow-up of one RCT) and 63 observational studies. The identified trials had some concern or high risk of bias. Most observational studies were downgraded on the Newcastle-Ottawa scale due to lack of appropriate comparator groups. Studies used heterogenous outcomes of clinical responses, angiographic stabilization, normalization of inflammatory markers, reduction in vascular uptake on positron emission tomography, reduction in prednisolone doses and relapses. Tocilizumab showed benefit in a RCT compared to placebo in a secondary per-protocol analysis but not the primary intention-to-treat analysis. Abatacept failed to demonstrate benefit compared to placebo for preventing relapses in another RCT. Pooled data from uncontrolled observational studies demonstrated beneficial clinical responses and angiographic stabilization in nearly 80% patients treated with tumour necrosis factor alpha inhibitors, tocilizumab or leflunomide. Certainty of evidence for outcomes from RCTs ranged from moderate to very low and was low to very low for all observational studies. There is a paucity of high-quality evidence to guide the pharmacotherapy of TAK. Future observational studies should attempt to include appropriate comparator arms. Multicentric, adequately powered RCTs assessing both clinical and angiographic responses are necessary in TAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.